Poor sleep habits may put adolescents at higher risk for developing insulin resistance that could lead to type 2 diabetes and cardiovascular disease.
EN-374 granted rare pediatric disease, orphan drug designations for chronic granulomatous disease
Ensoma's lead program, EN-374, has been granted a pair of FDA designations for the treatment of X-linked chronic granulomatous disease.
Food Insecurity and the Dangers of Infant Formula Dilution
FDA approves non-invasive risdiplam tablet for spinal muscular atrophy
The new risdiplam tablet is suitable for those aged 2 years and older who weigh more than 44 lbs, according to Genentech.
Demystifying Infant Formula
FDA approves mirdametinib for patients 2 years, older with neurofibromatosis type 1
Efficacy for the kinase inhibitor was based on the ReNue (NCT03962543 ) trial that featured 58 adults and 56 pediatric patients.
The REACH Institute CEO Lisa Hunter Romanelli, PhD., honored as 2025 Elevate prize winner
The Elevate Prize Recognition and Investment Will Help Scale The REACH Institute’s Visionary Work to Address the Children’s Mental Health Crisis.